Welcome to our dedicated page for MNK news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on MNK stock.
Keenova Therapeutics plc reports company news around its branded therapeutics portfolio for rare and unaddressed conditions. Recurring updates cover financial results, clinical publications, disease-awareness campaigns, and presentations involving products and programs such as Acthar Gel, XIAFLEX, TERLIVAZ, and collagenase clostridium histolyticum research.
The company's communications emphasize specialty therapeutic areas that include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care. News also covers integration activity following its business combination, U.S. manufacturing operations, and portfolio performance drivers across established branded medicines.
Keenova Therapeutics (NASDAQ:MNK) announced management will present at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 10:00 a.m. GMT (5:00 a.m. ET). A live webcast and archived replay will be available via the company’s Investor Relations website at www.keenova.com.
The presentation provides investors a scheduled opportunity to hear management commentary and view the webcast recording.
Mallinckrodt (NYSE:MNK) reported third-quarter 2025 combined net sales of $753.1 million, a 49.0% increase versus Q3 2024, reflecting two months of Endo inclusion and Acthar® Gel strength.
Specialty Brands sales were $416.0 million (45.5% growth), including Acthar Gel net sales of $181.4 million (+43.5%) and XIAFLEX net sales of $90.1 million. Generics and Sterile Injectables totaled $337.1 million (53.6% growth).
GAAP net loss was $291.1 million; adjusted EBITDA was $111.3 million. Management raised full-year Acthar Gel growth guidance to 30%–35% and provided Q4 2025 guidance of $485M–$505M net sales and $155M–$165M adjusted EBITDA. Post-merger synergy targets: $75M run-rate first 12 months and $150M by year three.
Keenova Therapeutics (formerly Mallinckrodt, NYSE: MNK) completed the spin-off of Par Health on Nov 10, 2025 and rebranded to focus on branded therapeutics for rare and unmet conditions.
The company reported a 2024 pro-forma combined revenue of $1.7 billion, employs >1,600 people, and lists flagship products Acthar Gel and XIAFLEX. Keenova is headquartered in Dublin with a U.S.-focused commercial and manufacturing footprint.
The company intends to pursue a NYSE listing in 2026 and expects to conduct a public offering to facilitate the listing, subject to board approval and other conditions.
Mallinckrodt (NYSE:MNK) will present four posters, including one AASLD Poster of Distinction, at The Liver Meeting (AASLD) in Washington, D.C., Nov 7–11, 2025.
Presentations focus on hepatorenal syndrome (HRS) and TERLIVAZ (terlipressin), the first FDA-approved therapy to improve kidney function in adults with HRS‑AKI. Session: Portal Hypertension and Other Complications of Cirrhosis on Nov 8, 2025. Poster numbers: #2285 (Distinction), #2401, #2315, #2380. Key prescribing notes: patients with serum creatinine >5 mg/dL are unlikely to benefit. Important safety: boxed warning for serious or fatal respiratory failure; contraindications include hypoxia and active ischemia.
Mallinckrodt (NYSE:MNK) will report its third quarter 2025 financial results on Monday, November 10, 2025 before market open.
The company will host a conference call the same day at 8:00 a.m. ET with an audio webcast available in the Investor Relations section at ir.mallinckrodt.com under Events & Presentations. Participants can register to receive a dial-in number and personalized PIN; attendees are advised to join 10 minutes early. A replay of the webcast will be available after the event.
Mallinckrodt (NYSE:MNK) announced support for the inaugural Hepatorenal Syndrome (HRS) Awareness Day, established by the American Liver Foundation and observed annually on October 14 during National Liver Awareness Month.
The initiative aims to raise awareness, promote early detection and treatment, and share patient experiences. HRS is described in two types: HRS‑AKI (rapid, often requiring hospitalization) and HRS‑CKD (slower progression). The release states HRS affects more than 60,000 Americans annually (~0.01% of the U.S. population) and that hospitalization rates for HRS are increasing. Company and ALF leaders commented on the need to improve visibility and treatment options for patients.
Mallinckrodt (NYSE:MNK) has published findings from a cross-sectional physician survey and medical chart review regarding Acthar® Gel treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). The study, published in Open Access Rheumatology: Research and Reviews, demonstrated that some patients experienced positive treatment outcomes including reduced symptoms, decreased pain, improved physical function, and reduced corticosteroid use.
Acthar Gel, an FDA-approved complex mixture of ACTH analogs and pituitary peptides, is indicated for treating various autoimmune disorders and inflammatory conditions. The research provides valuable real-world data on the medication's clinical application and effectiveness in treating these complex arthritic conditions.
Mallinckrodt (MNK) has appointed Christiana Stamoulis as President and Chief Financial Officer, effective September 22, 2025. Stamoulis, currently EVP and CFO at Incyte, will succeed Bryan Reasons, who is departing to pursue other opportunities.
With approximately 30 years of biotechnology industry experience, Stamoulis brings extensive expertise in strategy, finance, and corporate development. Her appointment follows Mallinckrodt's recent merger with Endo, marking a significant transformation period for the company. In her new role, she will oversee the finance organization and lead corporate development initiatives.
Prior to Incyte, Stamoulis held leadership positions at Unum Therapeutics, Vertex Pharmaceuticals, and served as Managing Director at Citigroup's Investment Banking division. She holds two BS degrees and an MBA from MIT.
Mallinckrodt (MNK) reported Q2 2025 financial results and provided guidance following its merger with Endo. Legacy Mallinckrodt achieved net sales of $485.1M (down 5.7% YoY, but up 8.5% excluding Therakos divestiture) and net income of $2.4M. Legacy Endo reported flat revenues of $447.8M with a net loss of $59.6M.
Key highlights include Acthar Gel's highest growth in over a decade (up 48.8% to $175.1M) and XIAFLEX's 9.4% growth to $138.6M. The combined company projects 2025 net sales of $3.57B-$3.62B and adjusted EBITDA of $1.10B-$1.13B. The planned spin-off of Par Health remains on track for Q4 2025, with expected net sales of $1.72B-$1.75B.
The company raised Acthar Gel's 2025 growth guidance to 20-30% from high-single digits and reaffirmed XIAFLEX's high-single digit growth outlook.Mallinckrodt (NYSE:MNK) has appointed Leslie Donato to its Board of Directors, completing its nine-member board following the recent merger with Endo, Inc. As former Executive Vice President and Chief Strategy Officer of Cencora, Donato brings over 30 years of healthcare industry experience and a track record of executing successful M&A strategies, having deployed over $10 billion in capital at Cencora and contributing to a 130% market cap increase over five years.
The appointment follows Mallinckrodt's August 1, 2025 merger with Endo, creating a global therapeutics leader. The board now comprises four members from each legacy company, with Donato jointly selected as the ninth member. Her extensive experience includes leadership roles at Bayer Healthcare Pharmaceuticals and McKinsey & Company.